Emergent BioSolutions
Content From Emergent BioSolutions
-
Humanigen & Emergent Biosolutions Announce Agreement for Phase 3 Covid-19 Therapeutic Candidate
Lenzilumab™ is currently in a Phase 3 clinical trial evaluating patients hospitalized with COVID-19. Humanigen intends to file for EUA first quarter of 2021.News Releases Released on 03.04.2021
-
Emergent CDMO Capabilities - Perfecting Your Formula
Since 1998, Emergent BioSolutions has been a trusted source for solving some of the most complex and critical challenges in public health.Literature / Brochures Released on 03.04.2021
-
Delivering Peace of Mind in an Uncertain World
At Emergent BioSolutions, our mission is to protect and enhance life. In working together, we envision protecting or enhancing 1 billion lives by 2030.Literature / Brochures Released on 03.01.2021
-
Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration
to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense FundingNews Releases Released on 07.08.2020
-
Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing
for Johnson & Johnson’s Lead COVID-19 Vaccine CandidateNews Releases Released on 07.06.2020
-
Emergent BioSolutions to Invest $75 Million
in Canton Site and Expand Viral Vector and Gene Therapy CapabilityNews Releases Released on 06.18.2020
-
Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner
for AstraZeneca’s COVID-19 Vaccine CandidateNews Releases Released on 06.11.2020
-
Emergent BioSolutions Joins U.S. Government’s Warp Speed Program
in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and ManufacturingNews Releases Released on 06.01.2020
-
Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner
for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19News Releases Released on 04.23.2020
-
Emergent BioSolutions Partners with U.S. Government for Comprehensive Response
to Expedite Development of Plasma-Derived Therapy for COVID-19News Releases Released on 04.02.2020
-
Emergent BioSolutions Signs Development and Manufacturing Agreement
with Vaxart for their Experimental Oral Vaccine Candidate for Coronavirus DiseaseNews Releases Released on 03.18.2020
-
Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates
for the Treatment and Prevention of Coronavirus DiseaseNews Releases Released on 03.11.2020
-
Emergent BioSolutions Signs Development and Manufacturing Agreement
With Novavax for Experimental Vaccine Candidate for Coronavirus DiseaseNews Releases Released on 03.10.2020
-
Emergent BioSolutions Initiates NIAID-Funded Phase 1b Clinical Study
...News Releases Released on 02.01.2017
Related Content
-
Biologics, Proteins, Vaccines | Regulatory Affairs
What Will Change at FDA for 2021?
(R)evolution of the industry’s data, catalyzed by changes at FDA and what’s the likely impact to the pharmaceutical industry?Ben Locwin, Contributing Editor, International COVID-19 Advisor, Healthcare Futurist 04.01.21
-
Breaking News | Industry News | Promotions & Moves
Vibalogics Updates U.S. Leadership Team
Appoints new CFO, VP of quality and head of process sciences.Charles Sternberg, Assistant Editor 03.31.21
-
Breaking News | cGMP Manufacture | Fill/Finish | Industry News
GRAM Attains EU GMP Certification for Commercial Aseptic Fill/Finish
Recognizes manufacturing facility and processes are in compliance with GMP requirements and readiness to provide commercial aseptic fill/finish services.Kristin Brooks 03.30.21
-
cGMP Manufacture | Drug Development | Scale-up/Technology Transfer
Fast Track Automation in Pharmaceutical Manufacturing
Drug manufacturers turn to advanced automation technologies and project execution methodologies to reduce time, cost and riskSteve Zarichniak, Technical Solutions Consultant, Honeywell Process Solutions 03.25.21
-
Emergent CDMO Capabilities - Perfecting Your Formula
Since 1998, Emergent BioSolutions has been a trusted source for solving some of the most complex and critical challenges in public health.
-
Delivering Peace of Mind in an Uncertain World
At Emergent BioSolutions, our mission is to protect and enhance life. In working together, we envision protecting or enhancing 1 billion lives by 2030.
-
Breaking News | Collaborations & Alliances | Drug Development | Industry News | Solid Dosage/Creams/Ointments
Pfizer Partners with Medicines Manufacturing Innovation Center
To transform the formulation of oral solid dosage medicines.Tim Wright, Editor, Contract Pharma 02.25.21
-
Drug Delivery
Aerosol Delivery Devices Market
Advantages over conventional drug delivery devices, rise in prevalence of COPD and asthma drive the growth of the global aerosol delivery devices market.Allied Market Research 02.16.21
-
Bio News | Breaking News | Clinical Trial Materials | Clinical Trials | Collaborations & Alliances | Industry News
Humanigen, Emergent Enter Covid-19 Partnership
Sign contract development and manufacturing agreement for Phase 3 COVID-19 therapeutic candidate lenzilumab.Tim Wright, Editor, Contract Pharma 01.25.21
-
Targeted Protein Degradation at Syngene
Syngene has extensive experience in PROTACs
-
Breaking News | Industry News
KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
New lineup aims to address challenges from early stage powder characterization and formulation development to scale-up and production.Contract Pharma Staff 01.15.21
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Industry News
MilliporeSigma Acquires AmpTec
Expands mRNA capabilities for vaccines, treatments and diagnostics.Contract Pharma Staff 01.07.21
-
APIs | Breaking News | Facilities | Industry News
CordenPharma Colorado Increases US Peptide Manufacturing Capacity
Long-term expansion initiative approved to further increase flexibility, efficiency and ultimately, cost-effective production.Contract Pharma Staff 11.25.20
-
Excipients
Bye-Bye China?
Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.Michele Jermini and Enrico Polastro 11.17.20
-
Bio News | Breaking News | Facilities | Fill/Finish | Industry News | Parenterals
Fareva Expands Sterile Production Capabilities
Grows footprint with site acquisition in France and Austria.Contract Pharma Staff 11.06.20
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
Sanofi to Acquire Kiadis for $359M
Adds next-gen natural killer cell platform and pipeline of cell-based cancer immune-therapeutics and infectious disease therapies.Contract Pharma Staff 11.03.20
-
Breaking News | Collaborations & Alliances | Facilities | Industry News
Construction Starts on the Medicines Manufacturing Innovation Center
Will offer next-gen solutions in small molecule and pharmaceutical manufacturing.Contract Pharma Staff 10.26.20
-
Breaking News | Facilities | Industry News | QA/QC
Wuxi Griffin Completes Investment in New QC Lab and Storage Facility
Offers fully equipped microbiology and analytical testing lab for bulk and final product testing.Contract Pharma Staff 10.26.20
-
Bio News | Breaking News | Facilities | Industry News | Parenterals
INCOG BioPharma Launches Central Indiana Ops
New CDMO is investing roughly $60 million to construct and equip a 60,000-square-foot facility in Fishers.Contract Pharma Staff 10.19.20
-
Clinical Trials | Information Technology
Adding Remote Site Access to Sponsor Bids: What to Know as CRO
Traditional monitoring has changed, CROs should build a portfolio of remote access solutions and have them ready.Ryan Jones, CEO, Florence Healthcare 10.13.20
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
Lilly Submits EUA Request for COVID-19 Monotherapy
LY-CoV555 and LY-CoV016 combination therapy significantly reduced viral load at day 11, meeting the primary endpoint of the study.Contract Pharma Staff 10.07.20
-
Parenterals
Primary Packaging Considerations Amid COVID-19 Vax Urgency
Fran L. DeGrazio of West discusses why and how vaccine development is different than drug development and the impacts of COVID-19 on vaccine development.Kristin Brooks, Contract Pharma 10.05.20
-
Clinical Trials | Drug Development
Beyond 2020: The Future of CROs
How will remote site access impact the CRO business?Ryan Jones, CEO, Florence Healthcare 08.21.20
-
Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration
to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense Funding
-
Emergent BioSolutions to Invest $75 Million
in Canton Site and Expand Viral Vector and Gene Therapy Capability
-
Process Development for Scaled-up hESC/hiPSC Manufacturing
An optimized 14-day manufacturing workflow which produces > 10^10 , cells was developed in < 12 months
-
Frontage Laboratories' Hugh Davis
Frontage's chief business officer highlights the CRO's service offerings.Contract Pharma Staff
-
Drug Development | Drug Discovery
-
Bio News | Breaking News | Industry News | Information Technology
Goodwin Bio Launches Digitization Initiative
Invests in a sophisticated electronic quality solution.11.11.19
-
Catalent's Stacey Treichler
Catalent's product manager for biologics highlights key events.Contract Pharma Staff
-
Breaking News | cGMP Manufacture | Industry News
ANI Launches New CDMO Brand ANI Global Source
Following the integration of WellSpring, the specialty CDMO will support late stage development and commercial manufacture of pharmaceutical products.10.29.19
-
-
Emergent BioSolutions
Emergent provides contract development & manufacturing services for bulk drug substances and parenteral drug products.10.24.19
-
Contract Pharma’s 18th Conference & Tabletop Exhibit Was a Another Success!
Contracting & Outsourcing 2019 featured a sold-out exhibit hall and lively conference sessions.10.22.19
-
Breaking News
Contract Pharma’s 18th Conference & Tabletop Exhibit Was a Another Success!
Contracting & Outsourcing 2019 featured a sold-out exhibit hall and lively conference sessions.10.18.19
-
APIs
Better Drug Manufacturing Strategies: Custom APIs
Today’s biopharma companies are turning to their contractors for long-term collaboration and much higher levels of support.Tom Wilson, VP, Global Contract Manufacturing Leader, Pfizer CentreOne 10.15.19
-
VIDEO: Contract Pharma 2019 Video Highlights!
Contracting & Outsourcing 2019 featured a sold-out exhibit hall and lively conference sessions.10.02.19
-
-
-
Cytotoxics and High Potency Manufacturing
API to ADC: A Journey Through High Potency
This class of compounds represents a major advance in oncology research and treatment application.Maurits Janssen, Head Commercial Development API, Lonza Pharma & Biotech 09.16.19
-
Emergent BioSolutions
Emergent provides contract development & manufacturing services for bulk drug substances and parenteral drug products.09.13.19
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Industry News
Emergent Awarded 10-Year HHS Contract
To deliver ACAM2000 smallpox vaccine into the national stockpile09.06.19
-
Collaborations & Alliances | Drug Development
Gilead and Nurix to Collaborate on Novel Therapies
Consisting of targeted protein degradation drugs for patients with cancer and other challenging diseases06.20.19
-
Emergent BioSolutions, Inc.
Emergent BioSolutions provides contract manufacturing services for both bulk drug substances and sterile injectable drug products.04.19.19
-
Lyophilization
-
Bio News | Biologics, Proteins, Vaccines | Breaking News
Emergent Awarded U.S. Department of State Contract
Will supply medical countermeasures for chemical warfare agents03.08.19
-
-
Breaking News | cGMP Manufacture | Industry News
Emergent Expands Commercial Ops Capabilities
Adds ABEC CSR dual purpose single-use systems for large scale 750L microbial fermentation and 500L mammalian cell culture09.28.18
-
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Industry News
Emergent Buys Adapt Pharma for $735M
Joins effort to combat opioid overdose through acquisition of Adapt and its flagship product NARCAN Nasal Spray08.29.18
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
CEPI, Emergent and Profectus Enter Vaccine Mfg. pact
CEPI awards contract worth up to $36 million to develop Lassa virus vaccine08.21.18
-
Biologics, Proteins, Vaccines | cGMP Manufacture | Industry News
Emergent BioSolutions to Acquire PaxVax for $270M
Adds capabilities across R&D, manufacturing and commercial operations08.09.18
-
-
Facilities | Fill/Finish
Emergent Invests $50M to Expand Fill/Finish Facility
Multi-year investment will support growth of contract development and manufacturing capabilities06.07.18
-
Bio News | Breaking News | Drug Development | Drug Discovery | Industry News | Methods Development | Regulatory Affairs
Emergent Completes Market Authorization
For BioThrax (Anthrax Vaccine Adsorbed) in five Concerned Member States (CMS) within the European Union (EU)04.12.18
-
Industry News | Promotions & Moves
Emergent Appoints Key Executives
Robert G. Kramer Sr. will serve as president and COO, and Richard S. Lindahl will serve as EVP and CFO04.05.18
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News | Regulatory Affairs
FDA Approves Emergent’s Smallpox Vaccine
Will manufacture ACAM2000 in newly-acquired cGMP live viral manufacturing facility in Canton, MA12.01.17
-
Financial Reports
Financial Report: Emergent BioSolutions
Contract manufacturing revenue up 29% in the quarter11.03.17
-
2017 Contracting & Outsourcing Conference Wrap up
Another year of record attendance, sold-out exhibit hall, and sessions addressing key industry topics10.06.17
-
Bio News | Breaking News | Clinical Trial Materials | Clinical Trials | Drug Development | Industry News
Emergent BioSolutions Wins $63M BARDA Contract
Will develop treatment for cyanide exposure together with Southwest Research Institute09.18.17
-
Bio News | Breaking News | Facilities | Fill/Finish | Industry News | Injectables
Emergent Pays $125M for Sanofi’s Small Pox Biz
Addition of ACAM2000, the only FDA-licensed smallpox vaccine, expands and diversifies portfolio of medical countermeasures07.14.17
-
Bio News | Breaking News | Facilities | Industry News
Emergent Unveils Expanded Facility in Baltimore
The site will support the U.S. government’s national security and public health emergency needs05.17.17
-
Bio News | Breaking News | cGMP Manufacture | Industry News
Emergent BioSolutions Signs $53 Million BARDA Contract
Represents a modification of the current contract with the gov’t agency for the manufacture of botulism antitoxin04.10.17
-
Bio News | Breaking News | Facilities | Industry News | Validation
Emergent BioSolutions Receives BioThrax Approval
German Federal Ministry of Health approves the company’s Michigan facility for large-scale manufacturing02.03.17
-
-
-
Drug Development | Industry News
Aptevo Spin-off Receives $20M Emergent Payment
Final payment funds newly-launched oncology and hematology-focused company01.13.17
-
Breaking News | Industry News
IDT Biologika Establishes Animal Health Biz in U.S.
Veteran biopharma industry business officer José Ochoa will lead the new organization01.12.17
-
Emergent BioSolutions Announces Preliminary 2016 Financial Results and Provides 2017 Financial Outlo
...
-
-
-
-
Breaking News
IBT, Emergent BioSolutions in R&D Vax Pact
Emergent gains exclusive rights to IBT's vaccine antigens to develop and manufacture Filovirus vaccine11.15.16
-
-
-
Breaking News | Information Technology | Laboratory Testing | Promotions & Moves | Regulatory Affairs | Validation
Grand River Bolsters Executive Team
Names Colleen Herczak director of quality assurance and regulatory affairs07.14.16
-
DoD Selects Emergent’s Emergard Auto-Injector Platform
Will be tested for nerve agent antidote delivery04.26.16
-
Emergent Names Management for Spin-off
Bioscience company Aptevo Therapeutics to be operational mid-201604.21.16
-
Fill/Finish | Vials
Emergent BioSolutions
We provide contract manufacturing services for both bulk drug substances and sterile injectable drug products.03.09.16
-
Drug Delivery | Drug Development | Industry News
DoD Selects Emergent’s Emergard Auto-Injector Platform
Will be tested for nerve agent antidote delivery02.17.16
-
Breaking News | Promotions & Moves
Emergent Names Management for Spin-off
Bioscience company Aptevo Therapeutics to be operational mid-201601.21.16
-
Bio News | Biologics, Proteins, Vaccines | Clinical Trials | Drug Development | Regulatory Affairs
-
Biologics, Proteins, Vaccines | Drug Development | Fill/Finish | Financial Reports
Financial Report: Emergent BioSolutions
Contract manufacturing revenues up 20% in the quarter11.09.15
-
Breaking News | cGMP Manufacture | Industry News
Emergent BioSolutions Receives $44 Million CDC Contract
Further advances Vaccinia Immune Globulin intravenous program08.13.15
-
Breaking News | cGMP Manufacture | Drug Development | Fill/Finish | Industry News
Emergent to Spin-Off Biosciences Business
Emergent will retain the biodefense programs, platform technologies, and manufacturing infrastructure08.06.15
-
Bio News | Breaking News | Industry News | Injectables
Emergent Expands Biodefense Business
Launches military-grade auto-injector for emergency countermeasures08.03.15
-
Emergent BioSolutions to Release Second Quarter 2015 Financial Results and Conduct a Conference Call
Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, August 6, 2015 at 8:00 am (Eastern Time).
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Drug Development | Process Development
Emergent BioSolutions Awarded $19.7mn BARDA Contract
Will develop and manufacture Ebola monoclonal antibodies07.20.15
-
cGMP Manufacture | Process Development
Emergent Awarded $19.7 Million BARDA Contract to Develop and Manufacture Ebola Monoclonal Antibodies
Company Receives Its First Ebola-Related BARDA Task Order
-
Breaking News | Clinical Trial Materials | Clinical Trials | Drug Development | Drug Discovery | GMPs/GCPs | Trials & Filings
ProBioGen’s Avian AGE1.CR Cell Line Platform in Clinical Trials
Production of the first ever batch of MVA for a clinical trial using a cell line06.24.15
-
Inspections
Emergent BioSolutions Signs Long-Term Manufacturing Agreement With Prometic Life Sciences
Emergent Leverages Manufacturing and Plasma Fractionation Expertise to Create Opportunities for Future Revenue Growth
-
Breaking News | Clinical Trials | Collaborations & Alliances | GMPs/GCPs
Oxford University, GSK and Emergent BioSolutions Fight Ebola
Group initiates a prime boost study of Ebola vaccine candidates05.13.15
-
Oxford U., GSK, and Emergent Announce Initiation of a Prime Boost Study of Ebola Vaccine Candidates
...
-
Clinical Trials | Excipients
Emergent BioSolutions Expands Commercial Product Portfolio With FDA Approval of IXINITY
IXINITY is a Recombinant Factor IX Treatment for Hemophilia B
-
Bioassay Development | Breaking News | Drug Development | Methods Development | Process Development | Toxicology | Trials & Filings
-
Biologics, Proteins, Vaccines | Breaking News | Capsules | Clinical Trial Materials | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Industry News | Lyophilization | Process Development
-
Breaking News | Capsules | Extractables and Leachables | Facilities | Fill/Finish | Financial Reports | GMPs/GCPs | Lyophilization | Process Development
-
Breaking News | Chemistry | Industry News
Emergent Initiates BioThrax Study for Large Scale Production
Data will be used to support licensure of the new facility09.23.14
-
Bioassay Development | Breaking News | Collaborations & Alliances | Drug Development | Methods Development | Process Development | Toxicology
Emergent BioSolutions, MorphoSys Enter Prostate Cancer Drug Pact
Will initiate a Phase I trial of ES414 within the next six months08.20.14
-
Breaking News | Financial Reports
-
Breaking News | Fill/Finish | Financial Reports
-
Breaking News | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Industry News | Lyophilization | Process Development
Biodel, Emergent BioSolutions Enter Glucagon Mfg. Pact
To provide fill/finish of commercial quantities for GEM deviceKristin Brooks 03.06.14
-
Breaking News | Industry News
Cangene Acquisition Gets Ontario Court Approval
Emegent BioSolutions’ Plan of Arrangement includes purchase price of $222 millionKristin Brooks 02.19.14
-
Breaking News | Clinical Trials | Process Development | Promotions & Moves | Regulatory Affairs
Gallus BioPharma Appoints Quality & Regulatory VP
Kile brings 27 years of industry experienceKristin Brooks 02.12.14
-
Bioassay Development | Breaking News | Collaborations & Alliances | Drug Development | Methods Development | Process Development | Toxicology
ProBioGen, Emergent Expand Commercial Licenses
Gains broad access to viral vaccine production platformKristin Brooks 12.17.13
-
Breaking News | Financial Reports
-
Breaking News | Fill/Finish | Industry News
Emergent BioSolutions To Acquire Cangene
Expands manufacturing capabilities with fill/finish business in $222 million buyKristin Brooks 12.12.13
-
Bio News | Biologics, Proteins, Vaccines | Clinical Trials | GMPs/GCPs | Trials & Filings
Emergent Gets Positive Results in CLL Trial
Bio-treatment combined with Treanda shows responseGil Roth 12.09.13
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Clinical Trials | GMPs/GCPs | Inspections | Regulatory Affairs | Trials & Filings
Trials & Filings in Brief: Dec. 9, 2013
Eisai, Emergent BioSolutions, Gilead, Helsinn, Merck Serono, Novartis, QLTGil Roth 12.09.13
-
Breaking News | Promotions & Moves
Emergent BioSolutions Names EVP and General Counsel
Cruz to manage all legal matters and global compliance11.26.13
-
Breaking News | Promotions & Moves
Emergent BioSolutions Appoints EVP
To lead strategic direction and management of biosciences division08.16.13
-
Breaking News | Trials & Filings
Emergent BioSolutions Advances BioThrax Program
Phase III post-exposure study meets endpoints07.11.13
-
Emergent BioSolutions Advances BioThrax Program
Phase III post-exposure study meets endpoints07.11.13
-
Breaking News | Industry News | Process Development
GBI Awarded Process Development Sub-Contract
Will conduct process development for Anthrax Vaccine06.03.13
-
Breaking News | Industry News
Emergent BioSolutions Launches Singapore Operations
Emergent BioSolutions, Inc. has launched Singapore operations through EPIC Bio Ltd., a joint venture with Temasek Life Sciences Ventures Ltd. (TLV), to develop, manufacture, and commercialize pandemic influenza vaccines and therapeutics.10.08.10
-
Breaking News | Industry News
Emergent BioSolutions To Acquire Trubion
Trubion Pharmaceuticals, Inc. has signed an agreement to be acquired by Emergent BioSolutions, Inc. for approximately $96.8 million.08.13.10
-
-
Breaking News | Trials & Filings
